Publikationen in Zusammenarbeit mit Forschern von University of Belgrade (13)

2024

  1. Coumarins-lipophilic cations conjugates: Efficient mitocans targeting carbonic anhydrases

    Bioorganic Chemistry, Vol. 145

2023

  1. Biotinylated selenocyanates: Potent and selective cytostatic agents

    Bioorganic Chemistry, Vol. 133

  2. Structural, physicochemical and anticancer study of Zn complexes with pyridyl-based thiazolyl-hydrazones

    Journal of Molecular Structure, Vol. 1281

2022

  1. A Comprehensive Evaluation of Sdox, a Promising H2S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors

    Frontiers in Pharmacology, Vol. 13

  2. Straightforward access to novel mitochondriotropics derived from 2-arylethanol as potent and selective antiproliferative agents

    European Journal of Medicinal Chemistry, Vol. 228

  3. Study of the anticancer potential of Cd complexes of selenazoyl-hydrazones and their sulfur isosters

    European Journal of Medicinal Chemistry, Vol. 238

  4. Zn(ii) complexes with thiazolyl-hydrazones: structure, intermolecular interactions, photophysical properties, computational study and anticancer activity

    CrystEngComm, Vol. 24, Núm. 29, pp. 5194-5214

2021

  1. Structural, antioxidant, antiproliferative and in‒silico study of pyridine-based hydrazonyl‒selenazoles and their sulphur isosteres

    Journal of Molecular Structure, Vol. 1240

2020

  1. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells

    Investigational New Drugs, Vol. 38, Núm. 3, pp. 584-598

  2. Repurposing old drugs to fight multidrug resistant cancers

    Drug Resistance Updates, Vol. 52

2019

  1. Silver-based monomer and coordination polymer with organic thiocyanate ligand: Structural, computational and antiproliferative activity study

    Polyhedron, Vol. 173

2018

  1. Selenazolyl-hydrazones as novel selective MAO inhibitors with antiproliferative and antioxidant activities: Experimental and In-silico studies

    Frontiers in Chemistry, Vol. 6, Núm. JUL

2017

  1. DTA0100, dual topoisomerase II and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells

    European Journal of Pharmaceutical Sciences, Vol. 105, pp. 159-168